Laidlaw served as Co-Manager on the $21.75mm EyePoint Pharmaceuticals (EYPT) Follow-On Offering.
Laidlaw Capital Markets is pleased to announce today’s pricing of a $21,750,000 Follow-On Offering for EyePoint Pharmaceuticals (EYPT). Laidlaw proudly served as Co-Manager alongside Guggenheim, who was Sole Book-Runner on the transaction.
This link is provided as a service to you, and will take you to a third party site not affiliated with this site. We are not responsible for the content and do not guarantee the accuracy of any information or material contained therein
Laidlaw & Company provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site.